Novel zinc phthalocyanine as a promising photosensitizer for photodynamic treatment of esophageal cancer.

Photodynamic therapy (PDT) has gathered much attention in the field of cancer treatment and is increasingly used as an alternative solution for esophageal cancer therapy. However, there is a constant need for improving the effectiveness and tolerability of the applied photosensitizers (PS). Here, we propose tetra-triethyleneoxysulfonyl substituted zinc phthalocyanine (ZnPc) as a promising PS for photodynamic treatment of esophageal cancer. ZnPc-induced phototoxicity was studied in two human esophageal cancer cell lines: OE-33 (adenocarcinoma) and Kyse-140 (squamous cell carcinoma). In vitro studies focused on the uptake and intracellular distribution of the novel ZnPc as well as on its growth inhibitory potential, reactive oxygen species (ROS) formation and the induction of apoptosis. The chicken chorioallantoic membrane assay (CAM assay) and studies on native Wistar rats were employed to determine the antineoplastic and antiangiogenic activity of ZnPc-PDT as well as the tolerability and safety of non-photoactivated ZnPc in vivo. ZnPc was taken up by cancer cells in a dose- and time-dependent manner and showed a homogeneous cytoplasmic distribution. Photoactivation of ZnPc-loaded (1-10 µM) cells led to a dose-dependent growth inhibition of esophageal adenocarcinoma and squamous cell carcinoma cells of >90%. The antiproliferative effect was based on ROS-induced cytotoxicity and the induction of mitochondria-driven apoptosis. In vivo studies on esophageal tumor plaques grown on the CAM revealed pronounced antiangiogenic and antineoplastic effects. ZnPc-PDT caused long-lasting changes in the vascular architecture and a marked reduction of tumor feeding blood vessels. Animal studies confirmed the good tolerability and systemic safety of ZnPc, as no changes in immunological, behavioral and organic parameters could be detected upon treatment with the non-photoactivated ZnPc. Our findings show the extraordinary photoactive potential of the novel ZnPc as a photosensitizer for PDT of esophageal cancer.

[1]  A. Thrift.  The epidemic of oesophageal carcinoma: Where are we now? , 2016, Cancer epidemiology.

[2]  B. Nitzsche,et al.  Tetra-triethyleneoxysulfonyl substituted zinc phthalocyanine for photodynamic cancer therapy. , 2016, Photodiagnosis and photodynamic therapy.

[3]  Heidi Abrahamse,et al.  New Photosensitizers For Photodynamic Therapy , 1990, [1990] Proceedings of the Twelfth Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[4]  A. Esterman,et al.  Risk factors for Barrett’s esophagus: a scoping review , 2016, Cancer Causes & Control.

[5]  Y. Tsai,et al.  Quality-of-life measures as predictors of post-esophagectomy survival of patients with esophageal cancer , 2016, Quality of Life Research.

[6]  A. Behrens,et al.  Diagnostics and Early Diagnosis of Esophageal Cancer , 2015, Visceral Medicine.

[7]  Cédric Cochrane,et al.  Light emitting fabric technologies for photodynamic therapy. , 2015, Photodiagnosis and photodynamic therapy.

[8]  A. Musani,et al.  Photodynamic therapy of cancer — Challenges of multidrug resistance , 2015 .

[9]  Yejing Li,et al.  Charge dependent photodynamic activity of alanine based zinc phthalocyanines. , 2014, Journal of photochemistry and photobiology. B, Biology.

[10]  Sukki Cho,et al.  Clinical outcome of photodynamic therapy in esophageal squamous cell carcinoma. , 2014, Journal of photochemistry and photobiology. B, Biology.

[11]  M. Höpfner,et al.  Synthesis and characterization of novel zinc phthalocyanines as potential photosensitizers for photodynamic therapy of cancers , 2014, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[12]  T. Nagayasu,et al.  How to access photodynamic therapy for bile duct carcinoma. , 2014, Annals of translational medicine.

[13]  Patrycja Nowak-Sliwinska,et al.  Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization , 2014, Journal of cellular and molecular medicine.

[14]  Tingting Yang,et al.  Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. , 2014, Journal of pharmaceutical and biomedical analysis.

[15]  O. Kuznetsova,et al.  Photodynamic Therapy in Gastroenterology , 2013, Journal of Gastrointestinal Cancer.

[16]  H. Abrahamse,et al.  The primary subcellular localization of Zinc phthalocyanine and its cellular impact on viability, proliferation and structure of breast cancer cells (MCF-7). , 2013, Journal of photochemistry and photobiology. B, Biology.

[17]  Jingwei Shao,et al.  Intracellular distribution and mechanisms of actions of photosensitizer Zinc(II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. , 2013, Cancer letters.

[18]  H. Wolfsen,et al.  Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma , 2013, Clinical endoscopy.

[19]  B. Nitzsche,et al.  Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer , 2012, British Journal of Cancer.

[20]  B. Nitzsche,et al.  Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo , 2012, Investigational New Drugs.

[21]  B. Aggarwal,et al.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. , 2012, Antioxidants & redox signaling.

[22]  B. Nitzsche,et al.  Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. , 2012, International journal of oncology.

[23]  B. Nitzsche,et al.  AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. , 2011, International journal of oncology.

[24]  Dhermendra K. Tiwari,et al.  Bio-distribution and toxicity assessment of intravenously injected anti-HER2 antibody conjugated CdSe/ZnS quantum dots in Wistar rats , 2011, International Journal of Nanomedicine.

[25]  A. Griffioen,et al.  Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane , 2010, Angiogenesis.

[26]  M. Corbett,et al.  A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. , 2010, Health technology assessment.

[27]  R. Preissner,et al.  Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours , 2010, British Journal of Cancer.

[28]  T. Lim,et al.  Verteporfin PDT for non-standard indications—a review of current literature , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  R. Boyle,et al.  Photodynamic therapy: novel third‐generation photosensitizers one step closer? , 2008, British journal of pharmacology.

[30]  Francisco Sanz-Rodríguez,et al.  Photodynamic therapy of cancer. Basic principles and applications , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[31]  Robert Gurny,et al.  The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. , 2007, Advanced drug delivery reviews.

[32]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[33]  D. Schuppan,et al.  Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. , 2007, Biochemical pharmacology.

[34]  Tania Khan,et al.  Synthesis and photodynamic potential of tetra- and octa-triethyleneoxysulfonyl substituted zinc phthalocyanines , 2007 .

[35]  Hongtao Jin,et al.  Intravenous repeated-dose toxicity study of ZnPcS_2P_2-based-photodynamic therapy in Wistar rats , 2006, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[36]  D. Schuppan,et al.  Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. , 2006, Biochemical pharmacology.

[37]  M. Höpfner,et al.  Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer , 2006, International journal of cancer.

[38]  Zheng Huang,et al.  A Review of Progress in Clinical Photodynamic Therapy , 2005, Technology in cancer research & treatment.

[39]  Michael R Hamblin,et al.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. , 2004, Photodiagnosis and photodynamic therapy.

[40]  Mark O. Liu,et al.  Photodynamic applications of phthalocyanines , 2004 .

[41]  M. Zeitz,et al.  Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells , 2003, International Journal of Colorectal Disease.

[42]  M. Calin,et al.  Photodynamic therapy in oncology , 2006 .

[43]  Paul Baas,et al.  Photodynamic therapy in oncology. , 2006, The oncologist.

[44]  Nancy L Oleinick,et al.  The role of apoptosis in response to photodynamic therapy: what, where, why, and how , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[45]  D. Nicholson,et al.  From bench to clinic with apoptosis-based therapeutic agents , 2000, Nature.

[46]  W. Potter,et al.  Comparison of Photodynamic Targets in a Carcinoma Cell Line and Its Mitochondrial DNA-Deficient Derivative , 2000, Photochemistry and photobiology.

[47]  Peter K. Kik,et al.  Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD) , 1999, British Journal of Cancer.

[48]  N. Breusing,et al.  The outcome of 5‐ALA‐mediated photodynamic treatment in melanoma cells is influenced by vitamin C and heme oxygenase‐1 , 2011, BioFactors.

[49]  D. Nowis,et al.  Light and Light Sources for Pdt Direct Tumor Damage Mechanisms of Photodynamic Therapy , 2005 .